Localized gastric GISTs can be treated with laparoscopic surgery. Outcomes and similar long-term outcomes compared with open surgery. The authors have no funding or conflicts of interest to disclose. A Propensity Score-Matching Analysis

Qing-Feng Chen, MM, Chang-Ming Huang, MD, Mi Lin, MM, Jian-Xian Lin, MM, Jun Lu, MM, Chao-Hui Zheng, MM, Ping Li, MM, Jian-Wei Xie, MM, Jia-Bin Wang, MM, Qi-Yue Chen, MM, Long-Long Cao, MM, and Ru-Hong Tu, MM

Abstract: Published reports on laparoscopic resection of gastric gastrointestinal stromal tumor (GIST) were limited to small experiences and selection bias.

Two hundred fourteen patients who underwent primary gastric GIST resection at our institution (January 2006–December 2012) were identified from a prospectively collected database. Laparoscopic resections (LAP) were performed in 133 patients, and open resections (OPEN) were performed in 81 patients. The short- and long-term outcomes were analyzed using propensity-score matching (PSM) by comparing the clinicopathological factors between these groups.

The tumor resection method and tumor size were significantly different between the LAP and OPEN groups. After PSM, there were no differences (P > 0.05) in these clinicopathological factors. The LAP group had less blood loss and shorter operation time, time to first flatus, time to first fluid diet, time to gastric tube removal, and postoperative stay before PSM. In addition, there were no differences regarding the time of drainage tube removal or hospitalization expense. Other than the time of gastric tube removal, which was similar in these 2 groups, the short-term outcomes were similar before and after PSM. The rates of postoperative complications in the LAP and OPEN groups were 6.8% and 22.8%, respectively, before PSM (P = 0.001) and 5.6% and 22.5%, respectively, after PSM (P = 0.004). The multivariate analyses for complications showed that tumors were located in the middle of the stomach, and the operation method and proximal gastrectomy were independent risk factors before and after PSM. The rates of postoperative complications in the LAP and OPEN groups were 6.8% and 22.8%, respectively, before PSM (P = 0.001) and 5.6% and 22.5%, respectively, after PSM (P = 0.004). The multivariate analyses for complications showed that tumors were located in the middle of the stomach, and the operation method and proximal gastrectomy were independent risk factors before and after PSM. The 5-year cumulative survival rates in the LAP and OPEN groups were 95.4% and 85.9%, respectively, (P = 0.07) before PSM and 93.1% and 91.9%, respectively, (P = 0.69) after PSM (not significantly different).

Laparoscopic resection for gastric GISTs had better short-term outcomes and similar long-term outcomes compared with open surgery. Localized gastric GISTs can be treated with laparoscopic surgery.

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are the most common types of mesenchymal tumors of the gastrointestinal tract, and these tumors occur most frequently in the stomach (50%–70%).1-3 Complete resection is the primary treatment for gastric GIST. Most gastric GISTs are localized in the submucosa and grow distensibly. These tumors infrequently invade nearby lymph nodes.4 These unique biological characteristics provide favorable conditions for laparoscopic surgery. Since Lukaszczyk et al5 performed laparoscopic surgery for gastric stromal tumors for the first time in 1992, the safety and feasibility of the laparoscopic resection of gastric GISTs have been confirmed by several studies.6-10 However, selection bias (tumor size and location) may have been present in these previous studies. In addition, there is a lack of randomized controlled studies and reports on the long-term outcomes of laparoscopic gastric resection for gastric GIST. In nonrandomized controlled trials, propensity-score matching (PSM),11 which calculates the propensity score for each patient by the logistic regression model and analyze the matched-pair data, can control for selection bias. Therefore, this study summarizes the clinicopathological data for 214 patients who underwent resection of primary gastric GISTs at our institution from January 2006 to December 2014. PSM was used to investigate the short- and long-term effects of laparoscopic and open gastric resection for GISTs.

METHODS

Study Population

The study cohort consisted of 563 GIST (confirmed by pathology) patients at the Fujian Medical University Union Hospital from January 2006 to December 2014. The inclusion criteria were as follows: primary gastric GIST (confirmed by pathology) patients and R0 resection. The exclusion criteria were as follows: (1) GISTs originating outside the stomach, (2) treated with neither laparoscopic nor open surgery, (3) received preoperative chemotherapy or oral imatinib (IM) treatment,
Variables and Definitions

Body mass index (BMI) ≥ 25 was identified as overweight according to WHO criteria. Gastric GIST was graded by the modified National Institutes of Health (NIH) risk classification scheme. The mitotic rates were defined as the number of mitoses per 50 high-power fields. The tumor size was defined as the maximum tumor diameter. Blood loss was quantified via the operation or anesthesia records. Preoperative comorbidities were classified according to the Charlson comorbidity index (CCI), and postoperative complications were classified according to the Clavien-Dindo Classification scheme.

Surgery Procedures

The surgery types consisted of laparoscopic and open resection for gastric GISTs, and the tumor resection types were wedge resection, proximal gastrectomy, distal gastrectomy, and total gastrectomy.

Follow-Up

Specially trained researchers used outpatient records, visitation, letters, and telephone calls to follow up with the patients after the operation. The last follow-up period was March 2015. The follow-up information included survival status, postoperative review results, tumor recurrence, and (or) metastasis and adjuvant therapy. The survival time was calculated as the time from diagnosis to the last contact, the date of death, or the date that the survival information was collected.

RESULTS

Clinicopathological Characteristics

All of the patients’ tumor margins were negative, and there was no intraoperative tumor rupture. LAP patients were more likely to undergo gastric wedge resection and have smaller tumors compared with the open group (P < 0.05). We set nine indices as matching covariant variables for PSM, including age, sex, body mass index (BMI), tumor size, mitotic rate, modified NIH risk classification, tumor resection type, tumor location, and IM treatment after surgery. Finally, 71 patient pairs were enrolled in this study. There were no significant differences (P > 0.05) in tumor size, mitotic rate, modified NIH risk classification, tumor resection methods, or IM treatment after surgery between these groups after PSM (Table 1).

Perioperative and Postoperative Results

Before PSM and compared with the OPEN group, the LAP group had less blood loss, shorter operation time, time to first flatus, time to first fluid diet, time to gastric tube removal, and postoperative stay. The 2 groups did not differ in the drainage tube removal times or hospitalization expenses. The short-term outcomes were similar before and after PSM, other than the time of gastric tube removal, which was similar in these 2 groups after PSM (Table 2).

Postoperative Complications

The postoperative complications were categorized according to the Clavien-Dindo Classification scheme. The postoperative complication rates in the LAP and OPEN groups were 6.8% and 22.8%, respectively, before PSM (P = 0.001) and 5.6% and 22.5%, respectively, after PSM (P = 0.004). The percentages of category I-II complications were 4.5% and 19.8%, respectively, before PSM (P = 0.001) and 2.8% and 21.1%, respectively, after PSM (P = 0.001). There were no differences in the percentages of category III-IV complications between the LAP and OPEN groups, which were (2.3% and 2.5%) before PSM and (1.4% and 2.8%) after PSM, respectively (Table 3).

Univariate and Multivariate Analyses of Postoperative Complications

A univariate analysis showed that tumor location in the middle third part of the stomach, laparoscopic surgery, and
proximal gastric resection were close related to the postoperative complications before and after PSM. A further multivariate analysis showed that in terms of postoperative complications, laparoscopic surgery (OR = 0.27, 0.08–0.92) was a protective factor, while tumor location in the middle third part of the stomach (OR = 9.43, 1.87–47.59) and proximal gastric resection (OR = 6.82, 1.07–43.30) were independent risk factors (Tables 4 and 5).

### Long-Term Outcomes

A total of 200 patients (93.5%) were followed up before PSM. The median follow-up time was 35 months (range 1–111 months). And 132 patients (93.0%) were followed up after PSM, and the median follow-up time was 36 months (range 1–111 months). The 3-year cumulative survival rates of the LAP and OPEN groups were 98.0% and 91.0%, respectively (P = 0.056). The 5-year cumulative survival rates of the LAP and OPEN groups were 95.4% and 85.9%, respectively (P = 0.07) before PSM. However, after PSM, there were no differences in the 3- or 5-year cumulative survival rates between the LAP and OPEN groups (93.1% and 95.6%, P = 0.35; 93.1% and 91.9%, P = 0.69, respectively).

Before PSM, recurrence occurred in 9 (6.8%) and 11 cases (13.6%) in the LAP and OPEN groups, respectively. After PSM, recurrence occurred in 6 (8.5%) and 5 cases (7.0%) in the LAP and OPEN groups, respectively. These rates were not significantly different.
Table 2: Perioperative and Postoperative Results

| Variables                      | Before PSM | After PSM | P    |
|--------------------------------|------------|-----------|------|
| Operation time, minutes        | OPEN (n = 81) | LAP (n = 133) | 0.00 |
|                                | 190 ± 79   | 111 ± 52  |      |
| Blood loss, mL                 | OPEN (n = 71) | LAP (n = 71) | 0.00 |
|                                | 297 ± 549  | 35 ± 33   |      |
| Time to first fluid diet, days | OPEN (n = 81) | LAP (n = 133) | 0.00 |
|                                | 5.1 ± 2.2  | 4.0 ± 1.5 |      |
| Time to first flatus, days     | OPEN (n = 71) | LAP (n = 71) | 0.00 |
|                                | 3.9 ± 1.6  | 3.1 ± 1.0 |      |
| Time to gastric tube removal, days | OPEN (n = 81) | LAP (n = 133) | 0.02 |
|                                | 4.1 ± 2.0  | 3.8 ± 1.4 |      |
| Time to drainage tube removal, days | OPEN (n = 71) | LAP (n = 71) | 0.48 |
|                                | 8.1 ± 4.4  | 7.5 ± 4.1 |      |
| Postoperative stay, days       | OPEN (n = 81) | LAP (n = 133) | 0.04 |
|                                | 13.4 ± 6.5 | 8.6 ± 4.9 |      |
| Hospitalization expense (10,000 RMB) | OPEN (n = 71) | LAP (n = 71) | 0.73 |
|                                | 4.2 ± 2.2  | 4.2 ± 3.1 |      |

PSM = propensity-score matching, RMB = Renminbi.

Discussion

Surgery is the initial treatment for localized or potentially removable GISTs, and the surgical options are open or laparoscopic surgery. However, the choice of surgery method is influenced by several factors. For relatively young patients with healthy body conditions, smaller tumors or lower risks, laparoscopic operations are more likely to be performed. Therefore, these studies were conducted with a selection bias that decreases the comparability of these results and affects the results of the research. For example, in the study of Goh et al,6 the tumor size in the laparoscopic group was smaller than in the open group (3.1 cm vs 4.5 cm, P = 0.043). The very low to low risk cases in the open group accounted for 43% of the cases, and this proportion was 60% in the laparoscopic group. While Bischof et al controlled for selection bias by PSM, the data still contained differences between the resection methods and tumor sizes (Table 6). In this study, the patients whose tumor was small and located in the upper third of the stomach were more likely to receive laparoscopic surgery, and laparoscopic surgery was associated with a higher proportion of the use of wedge resection. These differences could bias the results. In retrospective studies, PSM could have balanced the confounding variables, and the results would have been similar to randomized controlled studies. PSM can greatly increase the comparability between groups. Therefore, this study used the PSM method to control for selection bias, tumor size, mitotic rate, risk classification, tumor location, resection method, and other clinicopathological characteristics to account for significant differences.

Table 3: Postoperative Complications Before and After PSM

| Variables                      | Before PSM | After PSM | P    |
|--------------------------------|------------|-----------|------|
| Total complication*            | OPEN (n = 81) | LAP (n = 133) | 0.00 |
|                                | 18 (22.2%) | 9 (6.8%)  |      |
| Grade I-II*                    | OPEN (n = 71) | LAP (n = 71) | 0.00 |
| Pneumonia                      | 16 (19.8%) | 6 (4.5%)  |      |
| Abdominal infection            | 11         | 4         | -    |
| Wound infection                | 1          | 1         | -    |
| Urinary tract infection        | 0          | 1         | -    |
| GI leaks                       | 1          | 0         | -    |
| Lymphatic fistula              | 2          | 0         | -    |
| Anastomotic block              | 1          | 0         | -    |
| Gastropexia                    | 1          | 1         | -    |
| Grade III-IV*                  | OPEN (n = 81) | LAP (n = 133) | 1.00 |
|                                | 2 (2.5%)  | 3 (2.3%)  |      |
| Anastomotic block              | 1          | 1         | -    |
| Adhesive intestinal obstruction | 0          | 1         | -    |
| Abdominal infection            | 0          | 1         | -    |
| Heart failure                  | 1          | 0         | -    |

GI = gastrointestinal, LAP = laparoscopic resections, OPEN = open resections, PSM = propensity-score matching.
* Repeat cases not included.
Historically, gastric GISTs were initially treated by open surgery. However, open surgery induces greater trauma for patients, and those patients recover slowly after surgery. Laparoscopic surgery has many advantages compared to open surgery, and these advantages have been confirmed by several randomized controlled trials for gastric cancer, colon cancer, and nephrectomy. In addition, laparoscopic surgery is being gradually used for the treatment of GIST. Scholars initially believed that the difficulty of laparoscopic surgery would increase when tumors were large or located in the lesser curvature, cardiac or pylorus regions. Furthermore, laparoscopic surgery could increase the risk of tumor rupture. In 2012, the European Society for Medical Oncology clearly stated that laparoscopic surgery is not recommended for large tumors. However, with the improvements of laparoscopic technology, the majority of researchers currently considered laparoscopic surgery to be a safe and feasible treatment for gastric GISTs when the potential complications are well managed. In 2014, the National Comprehensive Cancer Network (NCCN) guidelines also modified the old version of the guidelines regarding the tumor size limitation for laparoscopic surgery. In this study, the tumor sizes of the LAP group were 1 to 11.3 cm, and laparoscopic surgery was successfully performed for all of the tumors without any ruptures. To avoid tumor rupture, we attempted not to touch the tumor directly. Tissue separation, capture, anastomoses were performed in the normal gastric tissue surrounding the tumor. In addition, the tumor was removed from abdominal cavity with a specimen bag.

This study showed that the LAP group performed significantly better than the OPEN group regarding operation time, blood loss, and recovery of gastrointestinal function before and after PSM. Thus, laparoscopic operations for GISTs resulted in better short-term outcomes than open surgery. These results are consistent with previous literature reports. In addition, the results showed that laparoscopic surgery can reduce the

| TABLE 4. Univariate Analysis of Postoperative Complications |
|------------------------------------------------------------|
| **Variables** | **Univariate Analysis Before PSM** | **Univariate Analysis After PSM** |
|               | **OR** | **95% CI** | **P** | **OR** | **95% CI** | **P** |
| Female        | Ref    | —         | —     | Ref    | —         | —     |
| Male          | 1.43   | 0.63–3.27 | 0.38  | 1.45   | 0.55–3.80 | 0.45  |
| Age < 60 years| Ref    | —         | —     | Ref    | —         | —     |
| Age ≥60 years | 1.26   | 0.53–2.99 | 0.59  | 1.16   | 0.41–3.26 | 0.78  |
| BMI < 25      | Ref    | —         | —     | Ref    | —         | —     |
| BMI ≥25       | 0.56   | 0.16–1.97 | 0.37  | 0.43   | 0.09–1.98 | 0.28  |
| CCI ≤3        | Ref    | —         | —     | Ref    | —         | —     |
| CCI >3        | 0.98   | 0.45–1.78 | 1.00  | 0.98   | 0.54–2.88 | 1.00  |
| Size (cm)     | Ref    | —         | —     | Ref    | —         | —     |
| < 2           | 0.92   | 0.24–3.54 | 0.90  | 0.75   | 0.17–3.20 | 0.69  |
| 2–5           | 1.01   | 0.25–4.13 | 0.98  | 1.38   | 0.33–5.73 | 0.65  |
| 5–10          | 0.95   | 0.14–6.46 | 0.96  | 0.67   | 0.06–7.35 | 0.74  |
| >10           | —      | —         | —     | —      | —         | —     |
| Mitotic rates | Ref    | —         | —     | Ref    | —         | —     |
| ≤5/HPF        | 0.42   | 0.09–1.86 | 0.25  | 0.30   | 0.04–2.39 | 0.26  |
| 5–10/HPF      | 0.47   | 0.06–3.71 | 0.47  | 0.89   | 0.42–3.98 | 1.00  |
| >10/HPF       | —      | —         | —     | —      | —         | —     |
| Modified NIH risk classification | Ref    | —         | —     | Ref    | —         | —     |
| Extremely low | 1.01   | 0.26–3.96 | 0.98  | 0.90   | 0.21–3.89 | 0.89  |
| Low           | 1.00   | 0.24–4.08 | 1.00  | 1.19   | 0.28–5.06 | 0.81  |
| Moderate      | 0.53   | 0.09–2.87 | 0.46  | 0.49   | 0.07–3.28 | 0.46  |
| High          | 1.27   | 0.55–2.92 | 0.57  | 1.63   | 0.61–4.36 | 0.33  |
| Location      | Ref    | —         | —     | Ref    | —         | —     |
| Up 1/3        | 3.18   | 1.25–8.09 | 0.02  | 5.96   | 1.63–21.83| 0.01  |
| Middle 1/3    | 1.27   | 0.31–5.23 | 0.74  | 1.96   | 0.31–12.66| 0.48  |
| Down 1/3      | 0.25   | 0.10–0.59 | 0.00  | 0.21   | 0.06–0.65 | 0.01  |
| OPEN          | Ref    | —         | —     | Ref    | —         | —     |
| Tumor resection | 3.01   | 0.95–9.48 | 0.06  | 2.25   | 0.62–8.12 | 0.06  |
| Wedge resection | —      | 0.21      | —     | —      | —         | —     |
| Proximal gastrectomy | 1.36   | 0.42–4.41 | 0.61  | 1.26   | 0.32–5.00 | 0.68  |
| Distal gastrectomy | 0.44   | 0.05–3.46 | 0.43  | 0.52   | 0.06–4.33 | 0.58  |

BMI = body mass index, CCI = Charlson comorbidity index, HPF = high-power fields, NIH risk classification = National Institutes of Health risk classification scheme, PSM = propensity-score matching.
TABLE 5. Multivariate Analysis of Postoperative Complications

| Variables          | Multivariate Analysis Before PSM | Multivariate Analysis After PSM |
|--------------------|----------------------------------|---------------------------------|
|                    | OR  | 95% CI     | P     | OR  | 95% CI    | P     |
| Location           |     |            |       |     |            |       |
| Up 1/3             |     |            | 0.03  |     |            | 0.02  |
| Middle 1/3         | 3.75| 1.26–11.12 | 0.02  | 9.43| 1.87–47.59| 0.00  |
| Down 1/3           | 1.31| 0.23–7.51  | 0.75  | 3.48| 0.35–34.35| 0.29  |
| OPEN               |     |            |       |     |            |       |
| LAP                | 0.31| 0.12–0.75  | 0.01  | 0.27| 0.08–0.92 | 0.03  |
| Tumor resection    |     |            | 0.16  |     |            | 0.21  |
| Wedge resection    |     |            |       |     |            |       |
| Proximal gastrectomy| 4.21| 1.06–16.78 | 0.04  | 6.82| 1.07–43.30| 0.04  |
| Distal gastrectomy | 1.18| 0.29–4.92  | 0.82  | 1.09| 0.22–5.38 | 0.92  |
| Total gastrectomy  | 0.42| 0.05–3.49  | 0.42  | 0.65| 0.07–6.22 | 0.71  |

CI = confidence interval, LAP = laparoscopic resections, OPEN = open resections, OR = odds ratio.

FIGURE 2. A, Kaplan-Meier curves for OS between the LAP group and OPEN group before PSM ($\chi^2 = 3.207$, $P = 0.07$). B, Kaplan-Meier curves for OS between the LAP group and OPEN group after PSM ($\chi^2 = 0.155$, $P = 0.69$). C, Kaplan-Meier curves for PFS between the LAP group and OPEN group before PSM ($\chi^2 = 2.273$, $P = 0.13$). D, Kaplan-Meier curves for PFS between the LAP group and OPEN group after PSM ($\chi^2 = 2.273$, $P = 0.13$). LAP = laparoscopic resections, OPEN = open resections, OS = overall survival, PFS = progress free survival, PSM = propensity-score matching.
TABLE 6. Journals Reviewed

| Author and Year | Group | N  | Size (cm) | Operation Time (minutes) | Complication | Follow-up Time, (months) | Recurrence Rate | 5-year Survival Rate |
|-----------------|-------|----|-----------|--------------------------|--------------|--------------------------|----------------|----------------------|
| Goh et al⁶      | OPEN  | 39 | 4.5 (1.5–6.5) | 95                      | 7.7%         | 21 (2–72)                | 0              | —                    |
| 2010            | LAP   | 14 | 3.1 (0.7–6.5) | 150                     | 0            | 8 (3–60)                 | 6.7%           | —                    |
|                 |       |    |           |                          |              |                          |                |                      |
| Karakousis et al⁷| OPEN  | 40 | 4.3 (2.0–9.0) | 89                      | 25%          | 43 (0.1–139)             | 2.5%           | —                    |
| 2011            | LAP   | 40 | 3.6 (0.7–7.8) | 96                      | 15%          | 28 (0.3–70)              | 2.5%           | —                    |
|                 |       |    |           |                          |              |                          |                |                      |
| De Vogelaer et al⁸| OPEN  | 16 | 7.5 ± 7.0 | 155                     | 18.9%        | 71 (0.3–199)             | 37.5%          | 4/16                 |
| 2013            | LAP   | 37 | 5.6 ± 2.8 | 48.5                    | 2.7%         | 83 (2–163)               | 0              | 1/37                 |
|                 |       |    |           |                          |              |                          |                |                      |
| Bischof et al⁹  | OPEN  | 124| 4.0 (3.0–5.5) | 196                    | —            | 32 (the whole group)     | 3.2%           | —                    |
| 2014            | LAP   | 124| 3.9 (2.3–5.2) | 157                    | —            | —                        | 1.7%           | —                    |
|                 |       |    |           |                          |              |                          |                |                      |
| Hsiao et al ¹⁰  | OPEN  | 21 | 6.0 ± 0.9 | 113                     | —            | 67 (12–133)              | 0              | —                    |
| 2015            | LAP   | 18 | 6.3 ± 1.1 | 146.6                   | —            | 37 (17–133)              | 5.6%           | —                    |
|                 |       |    |           |                          |              |                          |                |                      |
| Huang CM et al ¹⁰| OPEN  | 71 | 5.0 ± 2.6 | 186                     | 22.5%        | 46 (1–111)               | 7.0%           | 91.9%                |
| 2015            | LAP   | 71 | 4.9 ± 3.5 | 115                     | 5.6%         | 29 (26–77)               | 8.5%           | 93.1%                |

LAP = laparoscopic resections, OPEN = open resections.
incidence of postoperative complications, especially grade I-II complications. Wan et al\textsuperscript{22} compared 68 cases of laparoscopic surgery and 88 cases of open surgery, and the rates of postoperative complications were 5.9\% and 22.7\% in the LAP and OPEN groups, respectively (\(P = 0.004\)). The study conducted by Bischof et al\textsuperscript{9} also showed that the incidence of complications (more severe than grade III) after laparoscopic surgery was significantly lower than open surgery. In this study, the most common complication in the open group was pulmonary infection. The open operation results in greater trauma, a longer operation time, and a longer time until gastric tube removal. Furthermore, the postoperative digestive tract function recovery is slow. These factors may contribute to the increased rate of lung infections. We recommend that the operation times should be decreased as much as possible during open surgeries, and clinicians should monitor for pulmonary infections in patients with long times to gastric tube removal. Using a logistic regression analysis, we observed that laparoscopic surgery is a protective factor (OR = 0.27) for postoperative complications. Thus, laparoscopic surgery is safe and feasible for gastric GIST patients. In addition, proximal gastric resection (OR = 9.43) and tumors located in the middle third of the stomach (OR = 6.82) were independent risk factors for postoperative complications. The higher postoperative complication rates may result from the wide tumor separation ranges and more complex digestive tract reconstructions that are required during proximal gastrectomy. However, those patients whose tumor located in the gastro-esophageal junction or pylorus often require more difficult excisions as well as more complicated reconstructions. Unfortunately, such cases occupied only a small portion in total patients included in this study. Therefore, whether the conclusion that tumor location of middle third of the stomach is an independent risk factor of postoperative complications is correct remains to be discussed. A further large-scale or prospective clinical study about this issue will follow. We also found that these 2 groups did not differ in the hospitalization expenses. We think the reason is that the cost of laparoscopic surgery was higher than open surgery, but the operation time of open surgery was longer, and the incidence of complications was higher, which increased the hospitalization expenses of open surgery.

The prognosis of patients with gastric GIST was initially poor, and the 5-year survival rate was only 42\%.\textsuperscript{22} Recently, the prognosis of patients with GIST has improved significantly due to the improvement of surgical techniques and the clinical application of the molecularly targeted drug IM.\textsuperscript{11–25} In this study, the 5-year cumulative survival rates of the LAP and OPEN groups were 95.4\% and 85.9\%, respectively, before PSM. Thus, laparoscopic surgery has a better prognosis trend, although the \(P\) value was not statistically significant, which could have been due to the differences in the clinical and pathological characteristics of the 2 groups. After the selection biases of these 2 groups were balanced by the PSM method, the 5-year cumulative survival rates of the LAP and OPEN groups were 93.1\% and 91.9\%, respectively, and the rates were not statistically different. The long-term outcomes of laparoscopic and open surgery were similar, which was consistent with previous reports (Table 6), but larger sample sizes and prospective, multicenter randomized studies are still required to provide more accurate evidence.

In summary, laparoscopic resection for gastric GIST resulted in improved short-term outcomes and similar long-term outcomes compared with open surgery. Localized gastric GIST can be treated by laparoscopic surgery. In this study, there were differences in tumor location and size between the 2 groups before PSM. Although the significance of the results did not change obviously by the application of the PSM method, we believed that PSM could balance the confounding variables and the results would be closer to those from randomized controlled studies, which would greatly increase the comparability between the 2 groups. Thus, the effects of surgery methods on postoperative outcomes of GIST patients could be illustrated more objectively and exactly. Although this is a retrospective study, it can provide references for the subsequent randomized clinical studies.

**ACKNOWLEDGMENTS**

The authors are thankful to Fujian Medical University Union Hospital for her management of our surgical video and gastric cancer and GIST databases.

**REFERENCES**

1. Pidhorecky I, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. *Ann Surg Oncol.* 2000;7:705–712.
2. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Comp Physiciens*. 2010;8:S1–S41.
3. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. *Eur J Cancer*. 2002;38:S39–S51.
4. Erko IP, Moloshok AA, Zotov VN. Surgical treatment of gastro-intestinal stromal tumours. *Klin Khir.* 2013(10):18–20.
5. Lukaszczycz JJ, Preletz RJ. Laparoscopic resection of benign stromal tumor of the stomach. *J Laparoendosc Surg.* 1992;2:331–334.
6. Goh KBC, et al. Impact of the introduction of laparoscopic wedge resection as a surgical option for suspected small/medium-sized gastrointestinal stromal tumors of the stomach on perioperative and oncologic outcomes. *World J Surg.* 2010;34:1847–1852.
7. Karakousis GC, Singer S, Zhang J, et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (gists): a size-matched comparison. *Ann Surg Oncol.* 2011;18:1599–1605.
8. De Vogelaere K, Hoorens A, Haentjens P, et al. Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach. *Surg Endosc.* 2013;27:1546–1554.
9. Bischof DA, Kim Y, Dodson R, et al. Open versus minimally invasive resection of gastric gist: a multi-institutional analysis of short- and long-term outcomes. *Ann Surg Oncol.* 2014;21:2941–2948.
10. Hsiao C, Yang C, Lai I, et al. Laparoscopic resection for large gastric gastrointestinal stromal tumor (GIST): intermediate follow-up results. *Surg Endosc.* 2015;29:868–873.
11. Lonjon G, Boutron I, Trinquart L, et al. Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures. *Ann Surg.* 2014;259:18–25.
12. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol.* 2008;39:1411–1419.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.* 2004;240:205–213.
14. Silberhumer GR, Hufschmid M, Wrba F, et al. Surgery for gastrointestinal stromal tumors of the stomach. *J Gastrointest Surg.* 2009;13:1213–1219.
15. Kim KH, Kim MC, Jung GJ, et al. Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible? *World J Surg Oncol.* 2012;10:230.
16. Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med.* 1997;127:757–763.

17. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. *Am J Epidemiol.* 1999;150:327–333.

18. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res.* 2011;46:399–424.

19. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2012;23:vii49–vii55.

20. von Mehren M, Randall RL, Benjamin RS, et al. Gastrointestinal stromal tumors, version 2. 2014. *J Natl Compr Canc Netw.* 2014;12:853–862.

21. Wan P, Yan C, Li C, et al. Choices of surgical approaches for gastrointestinal stromal tumors of the stomach: laparoscopic versus open resection. *Dig Surg.* 2012;29:243–250.

22. Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. *Histopathology.* 2003;43:118–126.

23. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. *Curr Opin Oncol.* 2006;18:386–395.

24. Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. *Int J Cancer.* 2011;129:2533–2542.

25. Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour. *Eur J Surg Oncol.* 2011;37:319–324.